Via JESSICA DaMASSA, WTF Health

Former FDA Principal Deputy Commissioner and current President of the Verily Life Sciences Clinical Research Platform Amy Abernethy has a deep understanding of the future of clinical research, real-world evidence and personalized healthcare.

Amy testified before Congress a few weeks ago, answering their questions about some of the hottest technologies and emerging virtual models that are reshaping the way clinical data is collected for medical devices, Regulatory approvals for pharmaceuticals and digital health applications. We’re here to find out their questions, their reactions to her answers, and what she thinks is the inside scoop on the investments they might make and the policies they might explore to use more technology and decentralize clinical trials for new medical treatments Product and prescription drug development leads to greater equity, diversity and safety. That’s not all! We also had a brief chat about Cures 2.0 for the 21st Century and how the FDA is considering leveraging real-world data and real-world evidence to address high-level regulatory issues. Hot space to watch, Amy is excited!

In addition to a “fresh” analysis of the health tech policy landscape, Amy spoke about Verily’s next steps. It sounds like the company may make acquisitions in the future…